<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3733">
  <stage>Registered</stage>
  <submitdate>25/06/2012</submitdate>
  <approvaldate>25/06/2012</approvaldate>
  <nctid>NCT01630434</nctid>
  <trial_identification>
    <studytitle>International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation</studytitle>
    <scientifictitle>Prospective, International, Multi-Center, Randomized Clinical Investigation of TransMedics Organ Care System (OCS LUNG) for Lung Preservation and Transplantation</scientifictitle>
    <utrn />
    <trialacronym>INSPIRE</trialacronym>
    <secondaryid>OCS-LUN-03-2010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lung Preservation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - OCS Lung
Treatment: devices - Cold flush and storage

Experimental: OCS Lung (Treatment Group) - The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.

Active Comparator: Cold flush and storage (Control Group) - Donor lungs will be preserved using cold flush and storage (control group)


Treatment: devices: OCS Lung
OCS Lung will be used to preserve the donor lungs (Treatment Group).

Treatment: devices: Cold flush and storage
Donor lungs will preserved using standard cold flush and storage

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart &amp; Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation. - This composite is a single outcome measure.</outcome>
      <timepoint>Day 30 after transplantation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of International Society for Heart &amp; Lung Transplantation (ISHLT) PGD Grade 3 at 72 hours post-transplantation</outcome>
      <timepoint>72 hours after transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of ISHLT PGD Grade 2 or 3 at 72 hours post-transplantation</outcome>
      <timepoint>72 hours after transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient survival at day 30</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Registered primary double-lung transplant candidate

          -  Age &gt; or equal to 18

          -  Signed: 1) written informed consent document and 2) authorization to use and disclose
             protected health information</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior solid organ or bone marrow transplant

          -  Single lung recipient

          -  Multiple organ transplant recipient

          -  Chronic use of hemodialysis or diagnosis of chronic renal insufficiency</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>316</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>TransMedics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A prospective, international, multi-center, randomized controlled trial comparing
      preservation of donor lungs using OCS-Lung perfusion device (Treatment Group) to cold flush
      and storage (Control Group).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01630434</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Abbas Ardehali, MD</name>
      <address>Ronald Reagan Medical Center, UCLA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>